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Phenotypic Drug Screening
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& Sherry L. Voytik-Harbin1,6
While much progress has been made in the war on cancer, highly invasive cancers such as 
pancreatic cancer remain difficult to treat and anti-cancer clinical trial success rates remain low. One 
shortcoming of the drug development process that underlies these problems is the lack of predictive, 
pathophysiologically relevant preclinical models of invasive tumor phenotypes. While present-day 
3D spheroid invasion models more accurately recreate tumor invasion than traditional 2D models, 
their shortcomings include poor reproducibility and inability to interface with automated, high-
throughput systems. To address this gap, a novel 3D tumor-tissue invasion model which supports rapid, 
reproducible setup and user-definition of tumor and surrounding tissue compartments was developed. 
High-cell density tumor compartments were created using a custom-designed fabrication system and 
standardized oligomeric type I collagen to define and modulate ECM physical properties. Pancreatic 
cancer cell lines used within this model showed expected differential invasive phenotypes. Low-
passage, patient-derived pancreatic cancer cells and cancer-associated fibroblasts were used to increase 
model pathophysiologic relevance, yielding fibroblast-mediated tumor invasion and matrix alignment. 
Additionally, a proof-of-concept multiplex drug screening assay was applied to highlight this model’s 
ability to interface with automated imaging systems and showcase its potential as a predictive tool for 
high-throughput, high-content drug screening.
Despite progress in treating some cancers, metastatic tumors remain nearly impossible to treat, thus metastasis 
continues to be the predominant cause of cancer-related deaths1. This problem is especially apparent for highly 
metastatic cancers like pancreatic ductal adenocarcinoma (PDAC), where approximately 90% of patients present 
with invasive or metastatic disease2. While limited treatment options for patients with metastases represents a 
multi-facetted problem, one major shortcoming is the lack of predictive preclinical models of invasive tumor phe-
notypes that can be used for mechanistic studies, biomarker and drug target identification, and drug screening1,3. 
Since the initial step in the tumor metastatic process involves tumor cell engagement, remodeling, and invasion 
of the surrounding tissue extracellular matrix (ECM), it is becoming increasingly clear that accurate recreation 
of such three-dimensional (3D) tumor-tissue ECM interactions and associated physicochemical signaling is crit-
ical to the development of more pathophysiologically relevant and predictive in vitro models4,5. For PDAC, in 
particular, deposition of highly-crosslinked, fibrillar type I collagen by cancer associated fibroblasts (CAFs), also 
known as desmoplasia, represents a prominent ECM-associated change that has been implicated as a promoter of 
metastasis and a negative prognostic indicator6. Altogether, this points to a need for next-generation preclinical 
tumor-tissue invasion models that effectively recreate key features of the metastatic phenotype and this desmo-
plastic microenvironment.
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When developing next-generation in vitro phenotypic models of tumor invasion, a number of design criteria 
should be considered. Specifically, while there is advocacy that added model complexity (inclusion of vascula-
ture, various stromal and immune cells) may increase pathophysiologic relevance and predictive power, such 
approaches fall short with respect to practical logistics7–9. For such models to gain traction and widespread use 
within both pharmaceutical and academic environments, they must be user-friendly, time-efficient, reproducible 
within and between laboratories, standardizable, scalable, and ideally, amenable to high-throughput (HT) auto-
mation (e.g. automated imaging systems, liquid handling robots)7,10. Additionally, to achieve their full potential, 
in vitro phenotypic models should move beyond single population-level outcome measures, such as cytotoxicity, 
and incorporate high-content (HC) multiplex analyses of various relevant cellular processes and behaviors10,11. 
Much work has been done with traditional 3D multicellular spheroid models to demonstrate and improve the rel-
evance of these 3D models over 2D culture12–14, to assess the delivery and efficacy of therapeutics15,16, and to ena-
ble HT-HC screening through standardization and automation17–19. However, at present, few, if any, phenotypic 
invasion models achieve an appropriate balance between pathophysiologic relevance and practical considerations 
that enable translation to HT-HC screening7,8. Finally, since there remains a paucity of model standardization 
and validation in the published literature, phenotypic model readouts must be correlated with in vivo or clinical 
outcomes to effectively define their predictive power and accuracy20,21.
Conventional in vitro migration/invasion models (summarized in Table 1) include transwell (Boyden cham-
bers) assays, scratch or exclusion-zone assays, and 3D spheroid invasion assays22. Scratch and transwell assays are 
commonly used because of ease of use, although their geometry, artificial constraints, and general lack of ECM 
limit their physiologic relevance22. 3D spheroid invasion models, where multicellular tumor spheroids are embed-
ded within various 3D matrices, are becoming increasingly common22–24. However, adaptation and adoption 
of these models for HT-HC screens has been hampered by lack of standardization of both spheroid and matrix 
components and challenges associated with scaling. Other commonly cited shortcomings include: (1) time con-
suming nature of spheroid creation10,22; (2) lack of user control of spheroid size, shape, and cell density25,26; (3) 
reproducibility issues and questionable relevance of 3D matrix component27,28; and (4) lack of rapid, reproducible 
methods for spheroid embedment26.
To address the above-mentioned gaps, the goal of this work was to develop a HT-HC phenotypic screen-
ing model of PDAC invasion that supports user specification and control of both the tumor and the surround-
ing tissue compartment, improved pathophysiologic relevance in terms of cell-ECM interactions, and rapid, 
low-cost implementation. The proposed 3D tumor-tissue invasion model (Fig. 1a) was inspired, in part, by a 
“multi-tissue interface” model developed for vasculogenesis/angiogenesis studies and involved creation of two 
adjacent, independently tunable tissue compartments29. The use of standardized self-assembling oligomeric type 
I collagen (Oligomer) for creation of the interstitial ECM supports definition, customization, and standardiza-
tion of relevant physicochemical parameters, including molecular composition, intermolecular crosslink con-
tent, fibril architecture, and matrix stiffness. To adapt and extend this model for HT-HC phenotypic screening, a 
custom-designed, 96-well fabrication system was created and optimized (Fig. 1b). This low-cost, 3D-printed plat-
form supports precise definition and placement of the tumor compartment within the surrounding tissue com-
partment (Fig. 1c), which is essential for model interface with automated 3D image collection instruments. This 
work presents initial development and validation of this new 3D tumor-tissue invasion model which includes 
demonstrating pathophysiologically relevant modes of invasion by established PDAC cell lines, application of 
patient-derived PDAC cells and CAFs to recreate more complex heterogeneous cell-cell interactions and invasion 
mechanisms, and proof-of-concept (POC) drug dosing with image-based multiplex analysis of tumor cell prolif-
eration, metabolic activity, and invasion.
Criteria for relevant and translatable in vitro models
Scratch or 
exclusion zone
Transwell 
invasion
3D spheroid 
invasion
3D tumor-tissue 
invasion model
Relevance to metastasis
Tumor architecture and geometry
Cell monolayer on 
2D tissue-culture 
plastic
Cell 
monolayer on 
2D transwell 
insert
Self-aggregated 
multicellular 
spheroid 
embedded in 3D 
gel/matrix
User-defined tumor 
compartment embedded 
in 3D matrix
ECM microstructure thin layer or coating thin layer or coating
3D hydrogel or 
fibrillar collagen 
(monomer)
3D fibrillar collagen 
(Oligomer)
Accommodates heterogenous cell 
interactions no yes yes yes
Aspect of metastasis being modeled migration migration or invasion invasion invasion
Reproducible and 
standardizable setup
Setup time minutes minutes hours to days minutes
Reproducible setup yes yes no yes
User control of biophysical properties none
limited 
tunablity of 
surroundings
moderate 
tunablity of 
surroundings
high tunability of tumor 
and surroundings
Potential for HT-HC screening
Accommodates automated imaging 
and analysis yes no no yes
Measures multiple phenotypic 
readouts no no no yes
Table 1. Comparison of common in vitro invasion/migration models.
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Results
Custom fabrication system supports rapid, reproducible tumor-tissue invasion model setup. 
Since cost, complexity and compatibility with HT screening instruments are viewed as key barriers to more wide-
spread adoption of advanced 3D models30, our initial efforts focused on the design of a low-cost fabrication sys-
tem that facilitated rapid and reproducible tumor-tissue invasion model creation within standard 96-well plates. 
As shown in Fig. 1, the 3D printed system comprised a well-plate guide and fabrication platform consisting of 
an array of posts spaced 9 mm apart to match standard 96-well plate specifications (Supplemental Fig. S1). Post 
tips were concave-shaped to provide the necessary surface area and surface tension for creation, adhesion, and 
transfer of 5-µL liquid droplets. Post diameter and length, 1.8 mm and 9.9 mm respectively, were optimized so 
that the tumor compartment could be reproducibly and precisely positioned within the center of each well, 1 mm 
from the well bottom, in user-friendly fashion. This precise positioning of the tumor compartment (5 µL) within 
the surrounding tissue compartment (100 µL) facilitates automated collection and analysis of 3D confocal image 
stacks from the same region within each tumor-tissue construct. When used in conjunction with a multi-channel 
pipette, this platform supported rapid model setup (a full 96-well plate within 30 minutes) by various users.
Tumor-tissue invasion model supports customization and standardization of tumor and tis-
sue ECM physicochemical properties. Tumor invasion represents a complex, dynamic process which 
depends not only upon heterogeneous cell-cell interactions and soluble factor signaling but also ECM make-up, 
architecture and mechanics4,31,32. As such, the ability to define, tune, and standardize relevant ECM composition 
and biophysical properties in 3D models is essential for mechanistic studies and drug screening, as well as intra- 
and inter-laboratory reproducibility of model results33. Table 2 compares ECM formulations commonly used for 
invasion models, namely basement membrane extracts (e.g., Matrigel), monomeric type I collagen (atelocollagen 
and telocollagen), and type I collagen Oligomers. As shown in Table 2, specific advantages of Oligomer include 
its defined molecular composition and purity, standardized polymerization (self-assembly) specified by starting 
Figure 1. Overview of 3D tumor-tissue invasion model and fabrication system. (a) (i) Schematic of 3D tumor-
tissue invasion model and (ii) a representative image of tumor cells (Panc-1) invading into the surrounding 
matrix. Image represents 16 fields of view, each of which is a maximum projection of a 400 μm z-stack (20 μm  
step; 21 slices) after 5 days of culture; green = actin (phalloidin), blue = nuclei (Hoechst 33342), and 
red = fibrillar collagen (confocal reflectance). Scale bar = 400 μm (b) CAD drawing of custom-designed 
fabrication system used for rapid and reproducible model setup. (c) Process diagram of model setup. (i) 
Tumor cells suspended in Oligomer are pipetted (5 μL) onto the posts of the fabrication platform using a 
multi-channel pipet. (ii) Posts are covered with a 96-well plate, inverted, and incubated at 37 °C to induce 
Oligomer polymerization. (iii) Wells of a second 96-well plate are filled with Oligomer solution. (iv) After tumor 
compartment polymerization, the prefilled well plate is inverted and lowered onto the posts. (v) The plate is then 
flipped upright and incubated at 37 °C to polymerize tissue compartment. (vi) Fabrication platform is removed, 
and culture medium is added. Note: well-plate guide facilitates positioning of the well-plates over the posts of 
the fabrication platform.
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Oligomer concentration and rheometry-based stiffness of the polymerized matrix, and broad range of tunable 
matrix stiffness34,35. Unlike conventional collagen monomer formulations, Oligomer preserves the telopeptide 
ends of the collagen molecule, as well as its natural intermolecular crosslinks, which are known to (i) drive colla-
gen fibrillogenesis and self-assembly, (ii) provide resistance against rapid proteolytic degradation, and (iii) most 
importantly, be prevalent in mature tissues and tumor microenvironments36–39.
In the present work, collagen fibril density of the tumor and surrounding tissue compartments were inde-
pendently varied to define how fibril density affected PDAC phenotype and invasion as well as identify model 
parameters that allowed analysis of PDAC invasion within a 3- to 5-day time period. Oligomer formulations, 
representing 1.5 and 2.3 mg/ml were used, which corresponded to rheometric-determined stiffness values of 
200 and 500 Pa. Panc-1 cells were selected for these studies since they represent an established PDAC line that is 
known to be invasive, both in vitro and in vivo40,41. As shown in Fig. 2, both the number and maximum distance 
of invading Panc-1 cells decreased as the stiffness of the surrounding tissue compartment increased. By contrast, 
tumor matrix stiffness appeared to primarily affect the number of invading cells, with increased stiffness yielding 
a decrease in invasion cell number. Results showed that use of 200 Pa Oligomer for both the tumor and surround-
ing tissue compartment yielded the greatest level of invasion over a 5-day period. As such, these model conditions 
were selected for all subsequent experiments.
3D tumor-tissue invasion model recreates expected phenotype-dependent modes of tumor inva-
sion. PDAC invasion in vivo is a dynamic and plastic process where cells use a variety of invasion strategies to nav-
igate through the surrounding tissue27,32,42,43. While mechanisms underlying these different invasive phenotypes are 
not fully understood, it is known that tumor cells employ various collective or single-cell invasion modalities based on 
their epithelial-to-mesenchymal transition (EMT) phenotype and the balance of cell-cell and cell-ECM adhesions44–46. 
To demonstrate that our model can distinguish different invasive phenotypes, two established PDAC cell lines, Panc-1 
and BxPC-3 were compared. It is well established, by our laboratory and others, that Panc-1 and BxPC-3 have pro-
tein expression and behavior profiles consistent with mesenchymal and epithelial phenotypes, respectively40,47–49. 
Furthermore, while both lines express collagen-binding receptors, including α2β1 integrin48, only BxPC-3 expresses 
high levels of E-cadherin, a cell-cell junction protein thought to be necessary for collective invasion50.
As expected, Panc-1 invaded primarily as individual spindle-shaped cells, while BxPC-3 demonstrated 
collective-cell invasion with a leading front of single-cell invasion (Fig. 3a). Although a greater number (1.6-fold, 
p < 0.05) of BxPC-3 cells invaded the surrounding tissue, their maximum invasion distance was significantly 
(1.4-fold, p < 0.05) less than that of Panc-1 (Fig. 3b). Immunostaining further revealed that Panc-1 invasion was 
mesenchymal in nature with distinct spindle-shaped morphologies, prominent vimentin, and no E-cadherin 
expression (Fig. 4a). Confocal reflectance microscopy revealed substantial matrix remodeling associated with 
Panc-1 invasion, as indicated by uniform radial alignment of fibrils perpendicular to the tumor compartment 
boundary. By contrast, the majority of BxPC-3 cells maintained prominent E-cadherin expression, with a subpop-
ulation of vimentin-expressing cells found at the tumor-tissue boundary and invading the tissue compartment 
(Fig. 4a). Less matrix reorganization was observed with BxPC-3 with fibril alignment limited to regions between 
larger aggregates of invading cells (Fig. 4b). Finally, based on western blots, Panc-1 and BxPC-3 embedded within 
3D Oligomer appeared to downregulate β-catenin and ZO-1 compared to those grown on 2D tissue culture 
plastic (Supplemental Fig S2). Western blots also reveal upregulation of vimentin and N-cadherin for Panc-1 in 
Oligomer, with little discernable changes in E-cadherin for either cell type. Altogether, these results show that our 
model can distinguish phenotypically-different PDAC tumor cells, as well as EMT-dependent modes of invasion.
Incorporation of low passage patient-derived PDAC cells and CAFs recreates pathophysiologi-
cally relevant heterogeneous cell interactions and EMT-independent invasion. The cell interac-
tions between PDAC cells and CAFs are known to guide tumor progression, metastasis, and chemoresistance51–53, 
and are thus vitally important for accurate recreation of the tumor microenvironment in vitro8. To verify that our 
3D tumor-tissue invasion model could accommodate this increased complexity and provide additional mech-
anistic insight into PDAC-CAF interactions, co-culture conditions were established consisting of low-passage, 
Characteristic
Basement Membrane 
Extracts (e.g. Matrigel, 
Cultrex) Monomeric Type I Collagen Oligomeric Type I Collagen
Source EHS mouse tumor rat tail or bovine tendona pig dermisa
Primary component(s) laminin, type IV collagen type I collagen monomers type I collagen oligomers
3D structure non-fibrillar homogenous gel entanglement of long fibrils with little to no mature intermolecular crosslinks
highly interconnected fibril matrix 
with mature intermolecular crosslinks
User tunabilty poor moderate good
Mechanical stability poor poor good
Range of achievable 
stiffnessb 100%: 100 Pa
c 1–4 mg/ml: 9–343 Pad 1–4 mg/ml: 27–1440 Pad
Standardization overall protein concentration collagen concentration collagen concentration and shear storage moduluse
Table 2. Common 3D culture materials used for migration/invasion models. acan derived from other tissues, 
these are just common examples; bshear storage modulus; cref.47; dref.34; eASTM International Standard F3089-
14 (ref.88).
www.nature.com/scientificreports/
5SCientifiC RePoRTS |  (2018) 8:13039  | DOI:10.1038/s41598-018-31138-6
patient-derived PDAC cells (10.05) and CAFs. To aid in visualization and distinction of these two cell popula-
tions, 10.05 and CAFs were transfected to express TdTomato Red (TdT) and Enhanced Green Fluorescent Protein 
(EGFP), respectively (Fig. 5)54,55.
When incorporated into tumor compartment without CAFs, 10.05 cells were not invasive, growing as tight 
clusters (Fig. 5a), and little matrix remodeling was observed except for some matrix densification as indicated by 
the bright reflection signal immediately adjacent to the tumor compartment (Fig. 5b). Addition of CAFs resulted 
Figure 2. Surrounding matrix density (stiffness) is a primary determinant of tumor cell invasiveness. 
(a) The 3D tumor-tissue invasion model was created using 200 and 500 Pa Oligomer for both the tumor 
and surrounding tissue compartments. Tumor compartments were prepared with 1 × 107 Panc-1 cells/
mL in Oligomer and cultured 5 days. Images represent maximum projections of 150 μm confocal z-stacks; 
green = actin, blue = nuclei; scale bars = 100 μm. White dotted line represents boundary between tumor and 
surroundings. (b) Quantified tumor invasion is displayed as plots of (i) representative cumulative distribution 
of all invading cells from a single experiment, (ii) average number of invading cells, and (iii) maximum invasion 
distance. Bars represent mean ± SD (N = 3, n = 3); asterisks denote statistically different groups (p < 0.05). 
Legend denoting color-coding of bars applies to (ii) and (iii).
Figure 3. PDAC cells show phenotype-dependent invasion profiles. (a) The 3D tumor-tissue invasion model was 
created using 200 Pa Oligomer for both the tumor and surrounding tissue compartments. Tumor compartments 
were prepared with 1 × 107 Panc-1 or BxPC-3 cells/mL in Oligomer and cultured 5 days. Images represent either 
(i) 16 fields of view, each of which is a maximum projection of a 400 μm z-stack (scale bar = 400 μm) or (ii) a single 
maximum projection of 150 μm z-stack (scale bare = 100 μm); green = actin, blue = nuclei. White dotted line 
represents boundary between tumor and surrounding compartment. (b) Quantified tumor invasion is displayed 
as plots of (i) representative cumulative distribution of all invading cells from a single experiment, (ii) average 
number of invading cells, and (iii) maximum invasion distance. Bars represent mean ± SD (N = 3, n = 3); asterisks 
denote statistically different groups (p < 0.05).
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in a dramatically different phenotype with both 10.05 and CAFs invading the tissue compartment (Fig. 5a) with 
substantial matrix remodeling, as noted by obvious fibril alignment in the direction of invasion (Fig. 5b). CAFs 
appeared to physically guide tumor cell invasion, not only by creating a tension gradient in the fibril matrix, 
but also by altering the cell-cell adhesion balance, as invading 10.05 tumor cells were seen directly interfacing 
with CAFs (Fig. 5b,c). In terms of EMT protein expression, 10.05 tumor cells maintained prominent E-cadherin, 
while CAFs stained strongly for vimentin (Fig. 5c). Notably, although some 10.05 cells appeared more elon-
gated, this invasion phenotype maintained E-cadherin expression with no vimentin detected, suggesting either 
an EMT-independent mode of invasion or the early stages of EMT in which protein expression has not fully 
switched to the mesenchymal phenotype (Fig. 5c). Overall, these results demonstrate the ability of our model to 
Figure 4. PDAC cells demonstrate different invasive phenotypes. The 3D tumor-tissue invasion model was 
created using 200 Pa Oligomer for both the tumor and surrounding tissue compartments. Tumor compartments 
were prepared with 1 × 107 Panc-1 or BxPC-3 cells/mL in Oligomer and cultured 5 days. Constructs were fixed, 
cryosectioned, and immunostained for (a) vimentin (red) and E-cadherin (yellow) with nuclear counterstaining 
(blue; Hoechst 33342). Images represent maximum projections of 20 μm confocal z-stacks. (b) Sections were 
stained for vimentin (red) and imaged with confocal reflection microscopy to visualize matrix microstructure. 
Images represent maximum projections of 10 μm confocal z-stacks. Yellow arrowheads denote matrix 
remodeling and alignment. Scale bars = 50 μm.
www.nature.com/scientificreports/
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accommodate heterogeneous cell types relevant to PDAC desmoplasia as well as pathophysiologically relevant 
EMT-independent invasion.
3D tumor-tissue invasion model is amenable to automated HC drug dose screening. Since 
tumor invasion and metastasis is a complex process involving a variety of biological mechanisms, phenotypic 
assessment of the effects of therapeutic compounds requires quantification of multiple relevant outcomes. For 
example, disruption of tumor invasion can occur as a result of decreased tumor cell number, proliferation, motil-
ity, or a combination of these22,56. However, few, if any, current 3D in vitro invasion models have been designed 
with accompanying multiplex, optical assays to quantify measures of cell health along with relevant invasion 
metrics for HT-HC screening22,57. Therefore, to help fill this gap and more fully understand the effects of chem-
otherapeutic agents on tumor invasion, we developed a HT-HC assay for quantification of the above-mentioned 
endpoints.
Additionally, to demonstrate the amenability of our 3D tumor-tissue invasion model for HT-HC phenotypic 
screens, the multiplex assay was performed using an Opera Phenix High-Content Screening System. Gemcitabine, 
an analog of deoxycytidine which inhibits DNA synthesis, was selected as the drug of choice since it is clinically 
relevant in treatment regimens for PDAC patients58. The multiplex assay used Hoechst 33342 for nuclear detection 
and quantification of total cell number and invasion, Click-iT EdU to quantify proliferation, and MitoTracker Red to 
measure metabolic activity. Panc-1 and BxPC-3 cells were treated for 3 days with a 10-point dilution of gemcitabine, 
with 20 μM STS as a positive control and 1% DMSO serving as a vehicle control. Representative 3D image stacks of 
a single 96-well plate row are shown in Fig. 5a, highlighting model reliability and reproducibility for such applica-
tions. (See Supplemental Figs S3 and S4 for high magnification images). Note that the dark centers observed in some 
spheres is an imaging artifact due to imaging depth limitations and does not necessarily indicate a necrotic core.
Figure 5. CAFs enhance invasiveness of patient-derived PDAC cells. The 3D tumor-tissue invasion model 
was prepared with 200 Pa Oligomer for both the tumor and surrounding tissue compartments. Tumor 
compartments were created with 10.05 alone or 10.05 + CAFS (at 1:1 ratio) at 1 × 107 cells/mL in Oligomer 
and cultured 4 days. (a) Images represent nine fields of view, each of which is a maximum projection of a 400 
μm confocal z-stack. Red = tumor cells (TdT) and green = CAFs (EGFP). Scale bars = 200 μm. (b) Images 
represent maximum projections of 10 μm confocal z-stacks from cryosectioned constructs. Confocal reflection 
microscopy (white) was used to visualize matrix microstructure. Yellow arrowheads denote matrix alignment 
and remodeling; scale bars = 20 μm. (c) Images represent maximum projections of a 20 μm confocal z-stacks of 
cryosectioned constructs stained for E-cadherin (yellow) and vimentin (blue). Final panel represents a 3X zoom 
of boxed region in overlay panel. White arrowhead denotes direct interaction between tumor cell and CAF; 
scale bars = 50 μm.
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Analysis using Perkin Elmer’s Harmony software facilitated quantification of proliferation, metabolic activity, 
and invasion as a function of gemcitabine dose (Fig. 6b), as well as associated IC50 and Emax values (Fig. 6c). Here, 
relative IC50 is used to provide a measure of potency, and Emax represents the curve-fit value for the bottom plateau 
of dose response curves and provides a measure of efficacy. Consistent with gemcitabine’s mechanism of action, 
IC50 and Emax values for proliferative capacity were lower than those for metabolic activity and invasion for both 
Panc-1 and BxPC-3. On the other hand, both IC50 and Emax for proliferative capacity were not significantly differ-
ent between cell types, with values ranging from 1–4 nM and 0.3–4%, respectively. While gemcitabine effectively 
inhibited proliferation, it was found to be less potent and effective at killing tumor cells as indicated by signifi-
cantly higher IC50 and Emax values for metabolic activity. Both metabolic IC50 and Emax values for metabolic activ-
ity were greater for BxPC-3 compared to Panc-1; however, only IC50 value differences were statistically significant 
(p < 0.05). Finally, gemcitabine demonstrated only moderate inhibition of invasion in both BxPC-3 and Panc-1 
with Emax values not going below 25%, indicating incomplete eradication of invasion (Fig. 6b, panel iii). Together 
these results indicate that gemcitabine is potently and effectively blocking proliferation though not fully killing 
all cells or stopping invasion of tumor cells, even with concentrations up to 200 μM. Collectively, these results 
Figure 6. Proof-of-concept drug screen demonstrates HT-HC screening capacity. The 3D tumor-tissue 
invasion model was prepared with 200 Pa Oligomer for both the tumor and surrounding tissue compartments. 
Tumor compartments were prepared with 1 × 107 Panc-1 or BxPC-3 cells/mL in Oligomer and treated with 
serial dilutions of gemcitabine, 20 μM STS (cytotoxicity control), and 1% DMSO (vehicle control) for 4 days. 
(a) Images were obtained using an Opera Phenix. Representative images from a Panc-1 experiment represent 
maximum projections of 500 μm z-stacks. Columns represent different wells of a 96-well plate; rows represent 
(i) overlay of all channels, (ii) Click-it EdU 488 stained proliferating cells, (iii) MitoTracker Red stained 
active mitochondria, and (iv) Hoechst 33342 stained nuclei. (b) Representative dose response curves for (i) 
proliferative capacity, (ii) metabolic activity, and (iii) invasion for Panc-1 and BxPC-3. (c) Calculated (i) IC50 
and (ii) Emax values obtained from independent experiments (N = 3) and compared with Tukey-adjusted 
multiple comparisons. Letters over bars (mean ± SD) denote statistical differences; specifically, bars with the 
same letter are not statistically different, while those with different letters are statistically different (p < 0.05).
www.nature.com/scientificreports/
9SCientifiC RePoRTS |  (2018) 8:13039  | DOI:10.1038/s41598-018-31138-6
support the utility of this system for HT-HC phenotypic screening with the potential to identify and distinguish 
new or existing compounds’ effects on proliferation, metabolic activity, and invasion in a single HT-HC assay.
Discussion
The approval rate of anticancer therapies remains disappointingly low, with recent studies revealing that during 
the time period from 2004 to 2013, only 7.5% of drugs that entered phase I trials and only 33.2% of drugs that 
entered phase III trials were eventually approved59. These low approval rates, in addition to the exorbitant costs of 
drug development highlight the need for more efficient and predictive drug development workstreams, that apply 
predictive phenotypic models to bridge the gap between preclinical and human clinical outcomes8,57. In fact, one 
study using a quantitative decision theory model of pharmaceutical R&D provided evidence showing that the 
predictive validity of preclinical models should be prioritized over scale-up and cost reduction when working 
to achieve improved human therapeutic outcomes60. Further, even though metastasis and tumor invasion are 
the main cause of cancer deaths, most approved anti-cancer drugs (approximately 70%) inhibit proliferation or 
induce cell death, mirroring outcomes measured by traditional drug screening assays57. On the other hand, there 
are few drugs which target invasive phenotypes, in part, because there are few models which appropriately recre-
ate tumor invasion while maintaining the ability to quantify relevant outcomes for high throughput analysis7,57,61. 
In vitro 3D phenotypic models and microphysiologic systems are poised to effectively fill this gap in drug devel-
opment workflows as long as they are developed with the correct design considerations in mind.
Table 1 compares a number of present-day tumor migration/invasion models with regard to some of these 
important design criteria, revealing a paucity of models which balance pathophysiologic relevance and practi-
cal considerations for HT-HC screening7,8,20,21. Few of these models have been adapted for use in single-output 
HT screening, much less multiplex assays for HT-HC screening57. For example, Cribbes et al. applied multiple 
spheroid-based assays for evaluation of glioblastoma tumor invasion along with multiple phenotypic outcomes 
including spheroid size, live/dead staining, and apoptosis (Caspase 3/7). However, these outcomes were all meas-
ured in separate assays rather than a single multiplex assay62. Others have machined hemispherical pits into 
well-plate bottoms, facilitating reproducible placement of cell-collagen droplets which were subsequently over-
laid with collagen56. In this case, monomeric type I collagen was used for creation of tumor droplets and matrix 
overlay, which required the addition of dialdehyde dextran as an exogenous crosslinker to prevent contraction. 
Additionally, care was required when differentiating 2D migration from 3D invasion, since tumor droplets were 
not fully embedded63. To date, this example, as well as other 3D invasion models have not been paired with 
multiplex assays to assess drug sensitivity with multiple phenotypic outcomes56,64. In summary, while traditional 
2D cultures and floating multicellular spheroids have been paired with multiplex assays for HT-HC phenotypic 
analyses18,65,66, such assay formats have yet to be routinely used in conjunction with invasion/migration models57.
Another important differentiating feature between our model and previously published 3D invasion models is 
the application of oligomeric type I collagen to recreate and tune both the tumor stroma and adjacent tissue com-
partment. Oligomer molecules retain mature, trivalent intermolecular crosslinks, which are prevalent in mature 
tissues and have been implicated in tumor invasion and metastasis37,38,67. These natural crosslinks modulate the 
hierarchical packing and self-assembly of collagen-fibril tissues, imparting increased mechanical strength and 
proteolytic resistance (decreased turnover) without the need for exogenous crosslinking68. Thus, Oligomer creates 
a relevant desmoplasia-like environment and allows for systematic modulation of ECM physical properties such 
as fibril architecture, stiffness, and proteolytic degradability which can contribute to new mechanistic insight 
regarding the role of mechanobiology in tumor progression4.
While the most relevant mode of human tumor invasion remains unclear42, it is noteworthy that the invasive 
phenotypes observed in this 3D tumor-tissue invasion model align with observations from in vivo preclinical 
models as well as human clinical specimens. The mesenchymal, single-cell invasion exhibited by Panc-1 is con-
sistent with in vivo invasion as observed via intravital microscopy within a genetically engineered mouse model 
of pancreatic cancer with similar genetic mutations (p53 and KRAS)69. On the other hand, the collective cell 
invasion by “tumor buds” and partial EMT exhibited by BxPC-3 in our model, is reminiscent of another relevant 
invasive phenotype identified in serial sections of human PDAC42. Additionally, the cell-line dependent pheno-
types observed in this study align with results from both subcutaneous and orthotopic xenograft models in which 
BxPC-3 tumors remain more epithelial and clustered (differentiated) while Panc-1 tumors are more dispersed 
(undifferentiated), exhibiting more ECM remodeling, and modestly more invasion41,70,71.
When patient-derived cells and CAFs were embedded together within the tumor compartment, it was noted 
that CAFs greatly enhanced PDAC invasion, as is thought to occur in vivo72,73. Specifically, heterotypic cell-cell 
interactions observed in the present work are consistent with observations from human tumor samples and a 
spheroid invasion model in which heterotypic cadherin junctions form between invading cancer cells (squamous 
cell carcinoma and lung adenocarcinoma) and CAFs74. Additionally, in vitro and in vivo models of pancreatic and 
other cancers have shown that CAFs mediate tumor invasion through contractility-dependent matrix remodeling 
and alignment, similar to the matrix alignment noted in confocal reflection images (Fig. 5b) of the tumor-tissue 
invasion model75–77. Overall, these results with both the PDAC cell lines and the patient-derived PDAC cells and 
CAFs validate this model’s ability to recreate PDAC invasion and desmoplasia and to accommodate relevant het-
erogenous cell interactions. To further validate the relevance of this model, future studies are planned with other 
types of metastatic tumor cells (e.g. breast, lung, bladder) and with cells freshly isolated from patient tumors.
Finally, the multiplex assay and associated results showcase the utility of this 3D tumor-tissue invasion model 
for predictive HT-HC drug dosing and screening. Observations that gemcitabine is effective at inhibiting prolif-
eration while not fully eradicating the tumor or hindering invasion is consistent with its mechanisms of action as 
targeting DNA synthesis58. Additionally, these results align with those from PDAC xenograft models which show 
gemcitabine substantially hinders tumor growth and proliferation but does not induce significant apoptosis or 
reduction of distant metastases and invasion related markers78–80. These observations highlight the importance of 
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going beyond traditional screening assays which only assess cell viability or cytotoxicity and move into quantify-
ing multiple phenotypic parameters as we have done here. This type of HC analysis using a 3D phenotypic model 
opens the door for deeper mechanistic understanding of drugs and more predictive results earlier in the develop-
ment process11,81. While the present work only used one drug and a single set of matrix biophysical properties for 
model development and proof-of-concept purposes, future studies with this model include validating the HT-HC 
assay with drugs of different mechanisms of action (e.g. Paclitaxel, Marimastat, Mitomycin C), evaluating novel 
drug targets (e.g. STAT3, APE-1/Ref-1) and combination therapies, and defining how matrix biophysical prop-
erties, namely fibril density and intermolecular crosslinks, modulate drug transport (diffusivity) and cell phe-
notype, the interplay of which affects the overall drug response. Overall, these strategies, combined with recent 
advances in computational and animal models have potential to provide a more predictive preclinical portrait of 
a drug’s efficacy and toxicity to help bridge the gap between preclinical and human outcomes59,82,83.
In addition to this model’s potential as a HT-HC drug screening platform, there are many other applica-
tions for which it could be used. One such area is the emerging field of “mechanomedicine,” which is focused 
on identifying and developing therapeutics targeting mechanobiological mechanisms84. Because of the high 
degree of user control of both composition and biophysical properties in both tissue compartments, this 
tumor-tissue invasion model would be a powerful tool for systematic study of mechanobiology-related mech-
anisms thought to be involved in tumor invasion and metastasis4,85. Specifically, since it is thought that altered 
matrix stiffness, as mediated through changes in fibril density or intermolecular crosslinking, influences drug 
sensitivity, future studies will tune these biophysical properties (i.e. fibril density and collagen intermolecular 
crosslink content) of both tumor and surrounding compartments to characterize how cell-matrix adhesion bal-
ance and mechanotransduction guide tumor phenotype, drug transport and drug sensitivity. Transcriptomic 
data utilizing RNA sequencing could also aid in the mechanistic understanding of the differential expression 
between cells that remain in the tumor compartment and those that invade outward. Further, because of the 
size and robust nature of the embedded tumors, this model could be used as an in vitro platform to test ablative 
therapies—something not easily done with traditional 2D culture or spheroids7. Finally, with further develop-
ment and optimization this phenotypic model of invasion could be used as a high-content “culture and sensi-
tivity” screen for personalized medicine86.
Conclusion
With the ever-rising demand for more pathophysiologically relevant and predictive tumor models, it is impor-
tant to consider how these advanced models will translate and integrate with new or existing workflows. In this 
work, we aimed to develop a model system which accurately recreated specific features of human cancer while 
maintaining the ability to quantify relevant outcomes using high-throughput imaging systems. Specifically, our 
novel 3D tumor-tissue invasion model recreates PDAC desmoplasia and is able to quantify and distinguish var-
ious invasion strategies. Additionally, it allows for user customization and standardization; simple, rapid, and 
reproducible model creation; and automated imaging and analysis to enable HT-HC screening. With continued 
validation, this 3D tumor-tissue invasion model has great potential to serve as a predictive tool within new pre-
clinical drug development workflows to identify new anti-cancer therapies and decrease the high attrition rates 
of cancer clinical trials.
Methods
Cell culture. Established PDAC cell lines, BxPC-3 and Panc-1, were obtained from American Type Culture 
Collection (Manassas, VA) and were grown in RPMI-1640 (Life Technologies, Grand Island, NY) and high 
glucose DMEM (Hyclone, Logan, UT), respectively. Low-passage patient-derived PDAC cells, 10.05, as well as 
CAFs were grown in high glucose DMEM without sodium pyruvate (Life Technologies)54,87. All medium was 
supplemented with 10% heat-inactivated fetal bovine serum (HI FBS; Life Technologies). Medium for BxPC-3 
and Panc-1 was also supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin (Sigma Aldrich, St. 
Louis, MO), while 10.05 and CAFs were cultured in absence of antibiotics. Cells were maintained in a humid-
ified environment of 5% CO2 in air at 37 °C. All cells were passaged at 70–90% confluency; established PDAC 
lines and CAFs were used below passage 20. Patient-derived PDAC cells were used below passage 10, were 
authenticated by STR analysis (CellCheck with IDEXX BioResearch) and were tested regularly for mycoplasma 
contamination.
Creation of 3D tumor-tissue invasion model. Type I collagen Oligomer was derived from the dermis 
of market-weight pigs as previously described34. Oligomer was dissolved in 0.01 N hydrochloric acid (HCl) and 
standardized based on molecular composition and polymerization capacity according to ASTM International 
Standard F3089-1488. Here, polymerization capacity refers to the relationship (i.e., polynomial function) between 
shear storage modulus (G’, Pa) of the self-assembled matrix and Oligomer concentration. To achieve matrices of 
defined fibril density and matrix stiffness, Oligomer was diluted with 0.01 N HCl to desired concentration and 
neutralized to physiologic pH with a proprietary 10X Self-Assembly Reagent before the addition of cells. In this 
study, Oligomer matrices were prepared at stiffness values of 200 and 500 Pa (approximately 1.5 and 2.3 mg/mL, 
respectively). Validation that the high cell density used for tumor compartment formation did not significantly 
alter Oligomer self-assembly capacity was performed with 1.5 mg/ml matrices (data not shown).
The model fabrication platform was designed in SolidWorks (Dassault Systemes SolidWorks Corp., Waltham, 
MA) and 3D printed on a Fortus 400mc 3D Production System (Stratasys, Eden Prairie, MN) using acryloni-
trile butadiene styrene (ABS, Statasys). Overall dimensions and post spacing were optimized to accommodate 
glass-bottom 96-well plates (Cellvis, Mountain View, CA; Supplemental Fig. S1). A well-plate guide was created 
to aid in uniform and controlled placement of tumor compartments within all wells. The platform and well-plate 
guide were rendered aseptic by spraying with 80% ethanol and ultraviolet light exposure.
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Model setup using the fabrication platform is summarized in Fig. 1c. First, cells were suspended in neu-
tralized Oligomer at 1 × 107 cells/mL, and 5 μL drops were pipetted onto posts with a multi-channel pipette. 
For co-culture experiments, 10.05 tumor cells and CAFs were combined in the Oligomer-cell suspension 
at a 10.05 to CAF ratio of 1:1 while maintaining an overall cell concentration of 1 × 107 cells/mL. Once the 
Oligomer-cell suspension was pipetted onto the posts, the platform was covered with a 96-well plate, inverted 
and incubated at 37 °C for 8–10 min to allow Oligomer self-assembly. During this incubation time, the wells of 
another 96-well plate were filled with 100 μL of Oligomer. Once the tumor compartments were polymerized, 
this prefilled well plate was inverted and lowered onto the platform using the well-plate guide to position the 
posts in the center of each well and embed tumor compartments within Oligomer. This well plate was then 
flipped upright and incubated again at 37 °C for 15 min to allow full polymerization of the surrounding matrix. 
Subsequently, the fabrication platform was removed from the well plate and the appropriate medium added. 
Experiments comparing Panc-1 and BxPC-3 were cultured for 5 days while drug dosing experiments and those 
with patient-derived lines were 4 days.
Analysis of Tumor Cell Phenotype: Invasion and Epithelial to Mesenchymal Transition. For 
invasion analysis, tissue constructs were fixed with 3% paraformaldehyde (Mallinckrodt, Derbyshire, UK), per-
meabilized using 0.1% Triton X-100 (Sigma Aldrich), and stained to visualize F-actin (Alex Flour 488 or 546 
phalloidin; Life Technologies) and nuclei (Draq5 or Hoechst 33342; Life Technologies). Images were collected 
using laser scanning confocal microscopy with 10X objectives on either an Olympus IX81 (Olympus, Tokyo, 
Japan) or a Zeiss LSM 880 (Zeiss, Oberkochen, Germany). To quantify tumor invasion, image analysis was per-
formed on 3D renderings of confocal z-stacks in Imaris (Bitplane, Concord, MA) to obtain number of invading 
cells and invasion distance (details in Supplemental Methods). Two-factor ANOVA with Tukey-corrected pair-
wise comparisons (GraphPad Prism, GraphPad Software Inc., San Diego, CA) were used to determine statistical 
differences (p < 0.05).
To analyze epithelial to mesenchymal transition (EMT), 3D constructs were processed for immunostaining 
of specific protein markers. After fixation with 3% paraformaldehyde (Mallinckrodt), constructs were soaked 
in 30% sucrose solution, embedded in Optimum Cutting Temperature (OCT) compound (Fisher Healthcare, 
Houston, TX), and frozen overnight at −80 °C. Cryosections (60 μm) were prepared using a Thermo Cyrotome 
FE (Thermo Fisher, Kalamazoo, MI) and Superfrost Plus glass slides (Thermo Scientific). Sections were blocked 
with 1% bovine serum albumin (BSA; Jackson ImmunoResearch, West Grove, PA) followed by overnight incu-
bation at 4 °C with primary antibodies and 1-hour incubation at room temperature with secondary antibodies. 
Slides were then rinsed and mounted using Fluro-Gel (Electron Microscopy Sciences, Hatfield, PA). Primary 
antibodies included mouse anti-vimentin (V6389, Sigma Aldrich) and rabbit anti-E-cadherin (24E10, Cell 
Signaling Technologies, Danvers, MA). Matched species Alexa Fluor 405, 488, and 633 secondary antibodies (Life 
Technologies) were used to visualize via immunofluorescence. Slides were counterstained with Hoechst 33342 
(Life Technologies) for nuclei identification. Images were collected using laser scanning confocal microscopy with 
10X or 20X objectives.
Proof of Concept (POC) Multiplex Drug Screening Assay. For the POC multiplex drug screening assay, 
medium containing drugs was added 24 hours after model setup and every 24 hours thereafter for a total treat-
ment time of 72 hours (3 days). Gemcitabine (Alfa Aesar, Tewksbury, MA) was applied as a 10-point drug dilution 
with a starting concentration of 200 μM and a 1:5 dilution. Staurosporine (Alfa Aesar; 20 μM) and DMSO (Sigma 
Aldrich; 1%) were used as cytotoxicity and vehicle controls, respectively. For the high-content assay, Click-iT 
EdU Alexa Fluor 488 (ThermoFisher) and MitoTracker Red CMXRos (ThermoFisher) were used to measure 
proliferation and metabolic activity. Twenty-four hours prior to fixation, 10 μM 5-ethynyl-2′-deoxyuridine (EdU) 
and 500 nM MitoTracker were added in serum-free medium along with the final drug treatment. After fixation 
with 3% paraformaldehyde (Mallinckrodt), constructs were rinsed with 1% BSA (in 1X PBS), permeabilized 
using 0.1% Triton X-100 (Sigma Aldrich), and incubated overnight at 4 °C with Click-iT reaction cocktail pre-
pared according to manufacturer’s instructions. Finally, constructs were counterstained with Hoescht 33342 (Life 
Technologies) to visualize nuclei.
Automated confocal imaging was performed using an Opera Phenix High-content Screening System (Perkin 
Elmer, Waltham, MA). Image analysis was performed in Harmony Software (Perkin Elmer) to evaluate prolifer-
ative capacity, metabolic activity, and number of invading cells. (Refer to Supplemental Methods and 
Supplemental Fig. S5 for further details.) These three measures were each normalized to the cytotoxicity and 
vehicle controls using the following equation: = − − ×Response A% (A A )/(A ) 100%n STS DMSO STS . An repre-
sents the value of the nth dilution. ASTS and ADMSO represent values from the cytotoxicity control and vehicle 
controls, respectively. These values serve as internal standards to help in normalization of the data from 
plate-to-plate and within replicates. This data was used to fit three-parameter logistic curves in GraphPad Prism 
(GraphPad Software Inc.), from which IC50 and Emax values were calculated. These values were obtained from 
three independent experiments (N = 3) and compared using a one-factor ANOVA with Tukey-corrected pairwise 
comparisons to determine statistical differences (p < 0.05).
Data Availability
The data generated and analyzed during this study are included in this published article, in its supplementary 
Information, or are available from the corresponding author on reasonable requests.
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